The European Commission has granted orphan drug designation to Soligenix Inc.'s dusquetide (SGX945) for the treatment of Behçet Disease, following a positive recommendation from the European Medicines Agency. This designation provides up to 10 years of market exclusivity in the European Union and builds upon existing FDA orphan and fast track designations, positioning the company's innate defense regulator platform to address significant unmet medical needs in rare autoimmune conditions.
The decision was supported by Phase 2a data demonstrating biological efficacy and safety of dusquetide in treating Behçet Disease, a rare inflammatory disorder that can affect multiple body systems. This regulatory milestone is particularly significant given the limited treatment options currently available for this condition, which affects approximately 1 in 100,000 people in Europe according to Orphanet data. The orphan designation provides important incentives including protocol assistance, reduced regulatory fees, and market exclusivity upon approval.
Soligenix's development of dusquetide represents part of their broader innate defense regulator technology platform targeting inflammatory diseases. The company's Specialized BioTherapeutics business segment is also advancing HyBryte (SGX301) for cutaneous T-cell lymphoma treatment, with successful completion of a second Phase 3 study and plans to seek regulatory approvals worldwide. Additional development programs include expansion of synthetic hypericin (SGX302) into psoriasis treatment and dusquetide (SGX942) for oral mucositis in head and neck cancer patients.
The company's Public Health Solutions business segment continues development of vaccine candidates including RiVax for ricin toxin, filovirus vaccines targeting Marburg and Ebola viruses, and CiVax for COVID-19 prevention. These programs incorporate Soligenix's proprietary heat stabilization platform technology, ThermoVax, and have received government funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority. More information about the company's developments is available in their newsroom at https://ibn.fm/SNGX.
This European orphan drug designation represents a strategic advancement for Soligenix's Behçet Disease program, potentially accelerating development timelines and providing competitive advantages in the European market. For patients with this rare condition, the designation signals progress toward new therapeutic options that could address the significant unmet medical need in managing this complex autoimmune disorder. The company's continued advancement of its innate defense regulator platform demonstrates a focused approach to developing treatments for rare diseases with limited existing options.
